<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248816</url>
  </required_header>
  <id_info>
    <org_study_id>834574</org_study_id>
    <secondary_id>5P30AG03456-10</secondary_id>
    <nct_id>NCT04248816</nct_id>
  </id_info>
  <brief_title>Hepatocellular Carcinoma Surveillance in Cirrhotics</brief_title>
  <official_title>Increasing Surveillance Rates for Hepatocellular Carcinoma Among Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-arm pilot randomized controlled trial applying behavioral economic approaches
      (opt-out framing and financial incentives) to encourage patients with liver cirrhosis to
      complete regular surveillance ultrasounds which may allow for earlier diagnosis of and better
      outcomes for hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a substantial burden of HCC-related morbidity and mortality: The age-adjusted
      incidence rates of HCC have tripled in the US since the 1980s due to the burden of hepatitis
      C virus (HCV) and the epidemic of non-alcoholic fatty liver disease (NAFLD). The overwhelming
      majority of HCC in the US occurs in the setting of cirrhosis. Early diagnosis of HCC dictates
      survival: The American Association for the Study of Liver Diseases (AASLD) recommends
      biannual HCC surveillance for all patients with cirrhosis using an abdominal ultrasound.
      These guidelines seek to maximize early diagnosis of HCC which leads to earlier detection and
      improved survival because early-stage HCC is curable, with 70% 5-year survival compared to 5%
      in advanced disease.

      HCC surveillance rates are suboptimal: Despite longstanding published guidelines for HCC
      surveillance, adherence is low, with surveillance rates ranging from 15-30% in the US. Two
      RCTs have tested interventions to increase HCC surveillance, including electronic reminders
      for primary care providers and mailed reminders (with or without navigators), but neither has
      been scalable, produced durable responses, or increased surveillance rates above 50%.

      This is a 3-arm pilot randomized controlled trial applying behavioral economic approaches
      (opt-out framing and financial incentives) to encourage patients with liver cirrhosis to
      complete regular surveillance ultrasounds which may allow for earlier diagnosis of and better
      outcomes for hepatocellular carcinoma (HCC).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCC screening completion</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who have a surveillance abdominal ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCC screening method</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who have any hepatocellular carcinoma surveillance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opt-out</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facilitated outreach and opt-out framing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opt-out + Incentive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facilitated outreach and opt-out framing plus a financial incentive</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Subjects will receive outreach through their providers as is standard of care.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opt-out</intervention_name>
    <description>Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.</description>
    <arm_group_label>Opt-out</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Opt-out + Incentive</intervention_name>
    <description>Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.</description>
    <arm_group_label>Opt-out + Incentive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are 18+ years old

          -  Current diagnosis of cirrhosis

          -  2 or more visits to a Penn Gastroenterology/Hepatology practice in the preceding two
             years

          -  Must live in the Philadelphia Metropolitan Statistical Area

        Exclusion Criteria:

          -  History of HCC diagnosis

          -  Completed HCC screening within the past 9 months

          -  Patients with metastatic cancer

          -  Patients receiving hospice care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivan Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caitlin McDonald, MPH</last_name>
    <phone>215-615-1571</phone>
    <email>cmcdona@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Reitz, MPH</last_name>
    <phone>215-614-0282</phone>
    <email>catherine.reitz@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Caitlin McDonald, MPH</last_name>
      <phone>215-615-1571</phone>
      <email>cmcdona@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Reitz, MPH</last_name>
      <phone>215-614-0282</phone>
      <email>catherine.reitz@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shivan Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Shivan J Mehta</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Behavioral Economics</keyword>
  <keyword>Screening</keyword>
  <keyword>Outreach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

